Molecular modeling of ErbB4/HER4 kinase in the context of the HER4 signaling network helps rationalize the effects of clinically identified HER4 somatic mutations on the cell phenotype

Biotechnology Journal

Volumn 8, Issue 12, 2013, Pages 1452-1464

  Telesco, Shannon E ^a   Vadigepalli, Rajanikanth ^b   Radhakrishnan, Ravi ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cellular signaling pathways; Molecular dynamics; Network modeling; Receptor tyrosine kinase; Structural biology

Indexed keywords

ACTIVATION PROCESS; CELLULAR SIGNALING; MOLECULAR MECHANISM; MOLECULAR SIMULATIONS; NETWORK MODELING; RECEPTOR TYROSINE KINASE; SIGNALING NETWORKS; STRUCTURAL BIOLOGY;

AMINO ACIDS; MOLECULAR DYNAMICS; SIGNALING;

ENZYMES;

EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR 4 KINASE; HOMODIMER; JANUS KINASE; JANUS KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT5 PROTEIN; STAT5A PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; COMPARATIVE STUDY; CONFORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DEPHOSPHORYLATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HYDROGEN BOND; MOLECULAR DYNAMICS; MOLECULAR MODEL; NEGATIVE FEEDBACK; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATIC MUTATION; STEADY STATE;

CELLULAR SIGNALING PATHWAYS; MOLECULAR DYNAMICS; NETWORK MODELING; RECEPTOR TYROSINE KINASE; STRUCTURAL BIOLOGY;

COMPUTATIONAL BIOLOGY; HUMANS; MODELS, BIOLOGICAL; MOLECULAR DYNAMICS SIMULATION; MUTATION; PROTEIN SUBUNITS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84889635186     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201300022     Document Type: Article

References (67)

1. Yarden, Y., Sliwkowski, M. X., Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2001, 2, 127-137.
2. Citri, A., Yarden, Y., EGF-ERBB signalling: Towards the systems level. Nat. Rev. Mol. Cell. Biol. 2006, 7, 505-516.
3. Sweeney, C., Fambrough, D., Huard, C., Diamonti, A. J. et al., Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors. J. Biol. Chem. 2001, 276, 22685-22698.
4. Schlessinger, J., Cell signaling by receptor tyrosine kinases. Cell 2000, 103, 211-225.
5. Hubbard, S. R., Till, J. H., Protein tyrosine kinase structure and function. Ann. Rev. Biochem. 2000, 69, 373-398.
6. Linggi, B., Carpenter, G., ErbB receptors: New insights on mechanisms and biology. Trends Cell. Biol. 2006, 16, 649-656.
7. Schulze, W. X., Deng, L., Mann, M., Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol. Syst. Biol. 2005, 1, 2005.0008.
8. Birtwistle, M. R., Hatakeyama, M., Yumoto, N., Ogunnaike, B. A. et al., Ligand-dependent responses of the ErbB signaling network: Experimental and modeling analyses. Mol. Syst. Biol. 2007, 3, 144.
9. Choi, S. H., Mendrola, J. M., Lemmon, M. A., EGF-independent activation of cell-surface EGFreceptors harboring mutations found in gefitinib-sensitive lung cancer. Oncogene 2007, 26, 1567-1576.
10. Ji, H., Li, D., Chen, L., Shimamura, T. et al., The impact of human EGFRkinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006, 9, 485-495.
11. Lee, J. W., Soung, Y. H., Kim, S. Y., Nam, S. W. et al., ERBB2 kinase domain mutation in the lung squamous cell carcinoma. Cancer Lett. 2006, 237, 89-94.
12. Minami, Y., Shimamura, T., Shah, K., LaFramboise, T. et al., The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene 2007, 26, 5023-5027.
13. Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K. et al., Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005, 65, 1642-1646.
14. Willmore-Payne, C., Holden, J. A., Layfield, L. J., Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: Correlation with gene copy number, protein expression, and hormone receptor expression. Hum. Pathol. 2006, 37, 755-763.
15. Alimandi, M., Romano, A., Curia, M. C., Muraro, R. et al., Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995, 10, 1813-1821.
16. Da Silva, L., Simpson, P., Smart, C., Cocciardi, S. et al., HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res. 2010, 12, R46.
17. Wang, S. E., Narasanna, A., Perez-Torres, M., Xiang, B. et al., HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006, 10, 25-38.
18. Anglesio, M. S., Arnold, J. M., George, J., Tinker, A. V. et al., Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol. Cancer Res. 2008, 6, 1678-1690.
19. Feng, S. M., Sartor, C. I., Hunter, D., Zhou, H. et al., The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation. Mol. Endocrinol. 2007, 21, 1861-1876.
20. Muraoka-Cook, R. S., Feng, S. M., Strunk, K. E., Earp, H. S., 3rd, ErbB4/HER4: Role in mammary gland development, differentiation and growth inhibition. J. Mammary Gland Biol. Neoplasia 2008, 13, 235-246.
21. Tidcombe, H., Jackson-Fisher, A., Mathers, K., Stern, D. F. et al., Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality. Proc. Natl. Acad. Sci. USA 2003, 100, 8281-8286.
22. Clark, D. E., Williams, C. C., Duplessis, T. T., Moring, K. L. et al., ErbB4/HER4 potentiates STAT5A transcriptional activity by regulating novel STAT5A serine phosphorylation events. J. Biol. Chem. 2005, 280, 24175-24180.
23. Williams, C. C., Allison, J. G., Vidal, G. A., Burow, M. E. et al., The ErbB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J. Cell Biol. 2004, 167, 469-478.
24. Kabotyanski, E. B., Huetter, M., Xian, W., Rijnkels, M., Rosen, J. M., Integration of prolactin and glucocorticoid signaling at the beta-casein promoter and enhancer by ordered recruitment of specific transcription factors and chromatin modifiers. Mol. Endocrinol. 2006, 20, 2355-2368.
25. Kabotyanski, E. B., Rijnkels, M., Freeman-Zadrowski, C., Buser, A. C. et al., Lactogenic hormonal induction of long distance interactions between beta-casein gene regulatory elements. J. Biol. Chem. 2009, 284, 22815-22824.
26. Muraoka-Cook, R. S., Sandahl, M., Hunter, D., Miraglia, L., Earp, H. S., 3rd, Prolactin and ErbB4/HER4 signaling interact via janus kinase 2 to induce mammary epithelial cell gene expression differentiation. Mol. Endocrinol. 2008, 22, 2307-2321.
27. Muraoka-Cook, R. S., Sandahl, M., Husted, C., Hunter, D. et al., The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. Mol. Biol. Cell 2006, 17, 4118-4129.
28. Amin, D. N., Perkins, A. S., Stern, D. F., Gene expression profiling of ErbB receptor and ligand-dependent transcription. Oncogene 2004, 23, 1428-1438.
29. Amin, D. N., Tuck, D., Stern, D. F., Neuregulin-regulated gene expression in mammary carcinoma cells. Exp. Cell Res. 2005, 309, 12-23.
30. Soung, Y. H., Lee, J. W., Kim, S. Y., Wang, Y. P. et al., Somatic mutations of the ERBB4 kinase domain in human cancers. Int. J. Cancer 2006, 118, 1426-1429.
31. Tvorogov, D., Sundvall, M., Kurppa, K., Hollmen, M. et al., Somatic mutations of ErbB4: Selective loss-of-function phenotype affecting signal transduction pathways in cancer. J. Biol. Chem. 2009, 284, 5582-5591.
32. Telesco, S. E., Radhakrishnan, R., Structural systems biology and multiscale signaling models. Ann. Biomed. Eng. 2012, 40, 2295-2306.
33. Telesco, S. E., Shih, A. J., Jia, F., Radhakrishnan, R., A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine kinase signaling network. Mol. Biosyst. 2011, 7, 2066-2080.
34. Fedosov, D. A., Caswell, B., Karniadakis, G. E., A multiscale red blood cell model with accurate mechanics, rheology, and dynamics. Biophys. J. 2010, 98, 2215-2225.
35. Liu, Y., Purvis, J., Shih, A., Weinstein, J. et al., A multiscale computational approach to dissect early events in the Erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformations. Ann. Biomed. Eng. 2007, 35, 1012-1025.
36. Rausenberger, J., Hussong, A., Kircher, S., Kirchenbauer, D. et al., An integrative model for phytochrome B mediated photomorphogenesis: From protein dynamics to physiology. PLoS One 2010, 5, e10721.
37. Shih, A. J., Purvis, J., Radhakrishnan, R., Molecular systems biology of ErbB1 signaling: Bridging the gap through multiscale modeling and high-performance computing. Mol. Biosyst. 2008, 4, 1151-1159.
38. Vasalou, C., Henson, M. A., A multiscale model to investigate circadian rhythmicity of pacemaker neurons in the suprachiasmatic nucleus. PLoS Comput. Biol. 2010, 6, e1000706.
39. Purvis, J., Liu, Y., Ilango, V., Radhakrishnan, R., Efficacy of tyrosine kinase inhibitors in the mutants of the epidermal growth factor receptor: A multiscale molecular/ systems model for phosphorylation and inhibition. Proc. Foundations in Systems Biology II 2007, IRBVerlagStuttgart, 289-294.
40. Qiu, C., Tarrant, M. K., Choi, S. H., Sathyamurthy, A. et al., Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure 2008, 16, 460-467.
41. Fiser, A., Sali, A., Modeller: Generation and refinement of homology-based protein structure models. Meth. Enzymol. 2003, 374, 461-491.
42. Sali, A., Blundell, T. L., Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993, 234, 779-815.
43. Zhang, X., Gureasko, J., Shen, K., Cole, P. A., Kuriyan, J., An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125, 1137-1149.
44. Red Brewer, M., Choi, S. H., Alvarado, D., Moravcevic, K. et al., The juxtamembrane region of the egf receptor functions as an activation domain. Mol. Cell 2009, 34, 641-651.
45. Thiel, K. W., Carpenter, G., Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation. Proc. Natl. Acad. Sci. USA 2007, 104, 19238-19243.
46. Dixit, A., Verkhivker, G. M., Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: Thermodynamic and mechanistic catalysts of kinase activation by cancer mutations. PLoS Comput. Biol. 2009, 5, e1000487.
47. Papakyriakou, A., Vourloumis, D., Tzortzatou-Stathopoulou, F., Karpusas, M., Conformational dynamics of the EGFR kinase domain reveals structural features involved in activation. Proteins 2009, 76, 375-386.
48. MacKerell, A. D., Bashford, D., Bellott, M., Dunbrack, R. L. et al., All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 1998, 102, 3586-3616.
49. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., Klein, M. L., Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983, 79, 926-935.
50. Feller, S. E., Zhang, Y., Pastor, R. W., Brooks, B. R., Constant pressure molecular dynamics simulation: The Langevin piston method. J. Chem. Phys. 1995, 103, 4613-4621.
51. Phillips, J. C., Braun, R., Wang, W., Gumbart, J. et al., Scalable molecular dynamics with NAMD. J. Comput. Chem. 2005, 26, 1781-1802.
52. Humphrey, W., Dalke, A., Schulten, K., VMD: Visual molecular dynamics. J. Mol. Graph. 1996, 14, 33-38.
53. Glykos, N. M., Software news and updates. CARMA: A molecular dynamics analysis program. J. Comput.Chem. 2006, 27, 1765-1768.
54. Schoeberl, B., Pace, E. A., Fitzgerald, J. B., Harms, B. D. et al., Therapeutically targeting ErbB3: A key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci. Signal 2009, 2, ra31.
55. Yamada, S., Shiono, S., Joo, A., Yoshimura, A., Control mechanism of Jak/Stat signal transduction pathway. FEBS Lett. 2003, 534, 190-196.
56. Zi, Z., Zheng, Y., Rundell, A. E., Klipp, E., SBML-SAT: A systems biology markup language (SBML) based sensitivity analysis tool. BMC Bioinf. 2008, 9, 342.
57. Shih, A. J., Telesco, S. E., Choi, S. H., Lemmon, M.A., Radhakrishnan, R., Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond interaction networks in ErbB family kinases. Biochem. J. 2011, 436, 241-251.
58. Yang, S., Banavali, N. K., Roux, B., Mapping the conformational transition in Src activation by cumulating the information from multiple molecular dynamics trajectories. Proc. Natl. Acad. Sci. USA 2009, 106, 3776-3781.
59. Telesco, S. E., Radhakrishnan, R., Atomistic insights into regulatory mechanisms of the HER2 tyrosine kinase domain: A molecular dynamics study. Biophys. J. 2009, 96, 2321-2334.
60. Telesco, S. E., Shih, A. J., Liu, Y., Radhakrishnan, R., Molecular simulation of structure, dynamics, and function in the HER2 receptor tyrosine kinase and relevance to cancer mutations. Cancer Res. J. 2011, 4, 1-35.
61. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S. et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl. J. Med. 2004, 350, 2129-2139.
62. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S. et al., EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
63. Iyevleva, A. G., Novik, A. V., Moiseyenko, V. M., Imyanitov, E. N., EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: A case report. Urol. Oncol.-Semin Ori. 2009, 27, 548-550.
64. Mulloy, R., Ferrand, A., Kim, Y., Sordella, R. et al., Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res. 2007, 67, 2325-2330.
65. Sordella, R., Bell, D. W., Haber, D. A., Settleman, J., Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305, 1163-1167.
66. Shi, F., Telesco, S. E., Liu, Y., Radhakrishnan, R., Lemmon, M. A., ErbB3/HER3 intracellular domain is competent to bind atp and catalyze autophosphorylation. Proc. Natl. Acad. Sci. USA 2010, 107, 7692-7697.
67. Shih, A. J., Telesco, S. E., Radhakrishnan, R., Analysis of somatic mutations in cancer: Molecular mechanisms of activation in the ErbB family of receptor tyrosine kinases. Cancers 2011, 3, 1195-1231.